Tissue Diagnostics Market to Grow with a CAGR of 7.36% through 2028
Rising
incidences of cancer are expected to drive the Global Tissue Diagnostics Market
in the forecast period 2024-2028.
According to
TechSci Research report, “Tissue Diagnostics Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2028”, the Global
Tissue Diagnostics Market stood at USD 5.11 billion in 2022 and is anticipated
to grow with a CAGR of 7.36% in the forecast period, 2024-2028. Tissue
diagnostics continue to be the benchmark for cancer diagnosis, as they provide
detailed insights into tumor anatomy. As cancer cases increase, the tissue
diagnostics sector experiences strong demand and considerable growth prospects
in the foreseeable future. The tissue diagnostics industry was notably affected
by the COVID-19 pandemic, which resulted in a reduction in regular medical
procedures, including diagnostic tests, as healthcare priorities shifted
towards addressing the virus. The incidence of cancer is on a sharp rise,
inducing a fundamental shift in anatomic pathology. This transformation is
contributing to the continued expansion of the clinical pathology sector. The
digitization of diagnostic methods, the growing utilization of liquid biopsy
for cancer detection, and the ongoing convergence of anatomical and molecular
pathology are key drivers of this growth. Integrated bioinformatics and
analyses are gaining importance as computational pathology gains traction. Over
the last two decades, the tissue diagnostics industry has evolved significantly
with the availability of more advanced equipment, simplifying the tasks of
pathologists and healthcare professionals. For instance, in May 2021, QIAGEN
introduced its first FDA-approved tissue companion diagnostic designed to
detect the KRAS G12C mutation in NSCLC tumors. To enhance the accessibility of
precision medicine for lung cancer, this diagnostic tool was launched alongside
the Rotor-Gene Q MDx instrument, a component of the modular QIAsymphony family
of automation solutions. This achievement builds upon QIAGEN's nine years of
research and experience in developing and marketing KRAS CDx tests.
Tissue
diagnostics plays a pivotal role in modern healthcare, holding immense
importance in the diagnosis, treatment, and management of a wide range of
diseases, with cancer being a prominent example. This field involves the
examination of tissue samples, often obtained through biopsies, to uncover
crucial insights into the nature and extent of diseases at a cellular and
molecular level. First and foremost, tissue diagnostics serves as the gold
standard for cancer diagnosis. It allows pathologists and clinicians to
identify the presence of cancer, determine its type, stage, and aggressiveness,
and assess the effectiveness of treatments. This information is essential for
developing personalized treatment plans, which are increasingly vital in the
era of precision medicine. Moreover, tissue diagnostics aids in the diagnosis
of various other medical conditions, such as infectious diseases, autoimmune
disorders, and genetic abnormalities. It provides critical information for
selecting appropriate therapies, monitoring disease progression, and evaluating
treatment outcomes. In the research realm, tissue diagnostics supports
groundbreaking studies and clinical trials, facilitating the development of new
drugs and treatment modalities. Additionally, it contributes to our
understanding of disease mechanisms and the discovery of novel biomarkers,
which can guide future diagnostics and therapies. In summary, tissue
diagnostics is indispensable for accurate disease diagnosis, personalized
treatment strategies, research advancements, and overall improvements in
patient care and outcomes across a spectrum of medical conditions.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Global
Tissue Diagnostics Market”
the increasing
prevalence of cancer and other complex diseases is a significant driver. As
cancer rates surge worldwide, tissue diagnostics remain a cornerstone for early
detection, accurate diagnosis, and treatment planning. Secondly, the aging
global population contributes to the demand for tissue diagnostics. Elderly
individuals are more susceptible to various diseases, necessitating frequent
tissue analysis for timely interventions. Thirdly, the trend towards
personalized medicine fuels the market. Tissue diagnostics enable tailored
treatment strategies based on an individual's unique genetic and molecular
profile. Fourthly, technological advancements, such as digital pathology and AI
integration, enhance diagnostic accuracy and efficiency, attracting both
healthcare providers and patients. Furthermore, the expansion of healthcare
infrastructure in emerging economies and the increasing awareness about the
benefits of early disease detection are driving market growth. Lastly, the
rising investments in research and development activities, coupled with the
continuous quest for innovative diagnostic solutions, underscore the strong
growth prospects in the tissue diagnostics sector.
The Global
Tissue Diagnostics Market is segmented into product, technology, application, regional
distribution, and company.
Based on application,
the market is segmented into Breast Cancer, Prostate Cancer, Gastric Cancer,
and Other Cancers. The Breast Cancer is expected to rise in the forecast
period. Breast cancer is a global healthcare challenge, and tissue diagnostics
are indispensable for its identification, assessment, and treatment strategy
formulation. Sophisticated methods like immunohistochemistry and in situ
hybridization are gaining prominence for the examination of breast tissue
specimens, enabling accurate tumor profiling. This has led to an increased need
for specialized tissue diagnostics solutions tailored specifically for breast
cancer diagnosis and care. Additionally, research endeavors, bolstered by
government and private sector backing, are driving the innovation of effective
products designed for breast cancer diagnostics, thus propelling the market
growth in this particular application
Based on technology,
the market is segmented into Immunohistochemistry, In-Situ Hybridizations,
Digital Pathology and Workflow Management, and Others. The Immunohistochemistry
segment was dominated the market in 2022. This is due to its established role
in routine clinical practice. IHC offers precise protein-level information,
critical for cancer diagnosis and treatment decisions, making it a primary
choice for pathologists. In contrast, in-situ hybridization targets nucleic
acids, digital pathology focuses on imaging, and workflow management
streamlines processes but doesn't directly provide diagnostic information like
immunohistochemistry.
Major companies operating
in Global Tissue Diagnostics Market are:
- Nanoscribe
GmbH & Co. KG
- Stratasys
Ltd.
- 3D
Systems Inc.
- EOS
GmbH
- Renishaw
PLC
- Exone
Company.
- Formlabs
Inc.,
- Materialise
NV.
- SLM
Solutions Group AG
- Oxferd
Performance Materials, Inc
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The Global
Tissue Diagnostics Market is driven by several compelling factors that
collectively contribute to its rapid growth and innovation in the healthcare
industry. Firstly, the rising prevalence of cancer, growing awareness of cancer
therapies are the significant drivers. Elderly individuals are more susceptible
to various diseases, necessitating frequent tissue analysis for timely
interventions, propell the growth of Global Tissue Diagnostics Market. Additionally technological advancements, such as digital pathology
and AI integration, enhance diagnostic accuracy and efficiency, attracting both
healthcare providers and patients contributes to foster the demand for Global
Tissue Diagnostics Market in the forecast period” said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based management consulting
firm.
“Tissue
Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028 Segmented By Product (Instruments and Reagents, and
Consumables), By Application (Breast Cancer, Prostate Cancer, Gastric Cancer,
and Other Cancers), By Technology (Immunohistochemistry, In-Situ
Hybridizations, Digital Pathology and Workflow Management, and Others), By
Region and Competition” has evaluated the future growth potential of Global
Tissue Diagnostics Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Tissue
Diagnostics Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com